There is zero news or rumor to worry about. That said all stocks always have risk, and NEVER go straight up. There is ALWAYS risk (go look at Ariad as an example) - so I offer no guarantees. But, this product, how well they have executed clinical trials, the marketing agreement with JNJ (they recently did great job launching Zytiga in oncology) all point to upside with reduced risk when below $120. They are likely going to make a profit this year, without a drug on the market, because of the great deal they made with JNJ.